A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ One-hundred and thirty-five patients returned a completed questionnaire (75% response).
No significant differences were found between women with DCIS and invasive breast cancer on the physical and mental component scale of the RAND SF-36, nor on the WHO-5, which assesses well-being. In contrast, women with DCIS reportedly had a better physical health, better sex life and better relationships with friends/acquaintances than women the better prognosis of DCIS, it might be expected that women with DCIS report a better well-being and HRQL compared to women with invasive breast cancer. However, an American study among 76 DCIS patients demonstrated that approximately two years after diagnosis, one third of the patients still expressed fear about breast cancer, recurrence and metastasis, 3 indicating that such worries may persist several years after diagnosis and completion of treatment. There was a close correspondence between the concerns of women with DCIS about recurrence and those of women with invasive breast cancer. 3 It was not clear whether this was due to the lack of adequate information the patients received from the treating medical specialists or to other factors. A Canadian study including 64 women with DCIS and 164 women with invasive breast cancer also revealed no significant difference in distress and risk perception of DCIS and invasive breast cancer patients four months after treatment. 4 Despite the better prognosis, women with DCIS reported the same level of psychological morbidity and their risk perception of recurrence and dying of breast cancer was also similar to women with invasive breast cancer. 4 These remarkable findings of both studies may be explained in two ways. Patients with invasive breast cancer could have underestimated their risk or, alternatively, women with DCIS overestimated their risk.
In addition, the timing of the measurements may be a crucial factor. For example, the patients of the Canadian study completed the questionnaire shortly after their surgical procedure which can explain why women with DCIS expressed similar concerns as patients with invasive breast cancer. 4 In the present study, we compared the HRQL, perceived disease impact and risk perception of recurrence and dying of breast cancer of patients with DCIS and early-stage invasive breast cancer (EIBC) 2-3 years after treatment. In addition, a comparison was made with HRQL norm data from an age-matched population of Dutch women. Finally, we evaluated the women's understanding of their disease. Given the findings of the studies by Bluman and colleagues 3 and Rakovitch and colleagues, 4 we expected that Dutch women with DCIS have the same level of fear and similar worries as women with invasive breast cancer, implying that surgeons or nurse-practitioners should put extra effort in explaining the differences between both disease entities.
Patients and methods

Patients
The 
Logistics
Mailing of questionnaires at each participating hospital was coordinated and facilitated by the CCCS. The surgeons sent their patients a letter to inform them about the study together with the questionnaire. The patients also received a stamped return-envelope in which they could return the completed questionnaires, which only contained a study number preventing the researchers from tracking patient names by means of the patient numbers. All questionnaires were sent in May and June 2005. Completion of the self-administrated questionnaire was considered to imply informed consent.
Data collection and questionnaires
The questionnaire included questions about marital status, level of education (low = primary school; medium = secondary school; high = college/university) and current (at the time of survey) co-morbid conditions (asthma, COPD, heart diseases, hypertension, stroke, renal disease, diabetes mellitus, tumours, osteoarthritis, rheuma, skin diseases, liver disease and thyroid disease). In addition, HRQL, well-being, perceived disease impact, risk perception and understanding of the diagnosis were assessed as the main outcome variables. HRQL was assessed by using the Dutch version of the RAND SF-36 validated in Dutch cancer patients, 6 and wellbeing with the WHO-5. 7 As far as we know, the WHO-5 has not been used in cancer patients before. The Dutch version of the RAND SF-36 incorporates two composite scales; 8 the physical component scale (PCS) containing the sub-domains: physical functioning (PF), role limitations due to physical health problems (RP), bodily pain (BP) and general health perceptions (GH) and the mental component scale (MCS) containing the sub-domains: role limitations due to emotional problems (RE), general mental health (MH), vitality (VT) and social functioning (SF). 6 Each domain and summary scale is standardised on a scale from 0 to 100, with higher scores indicating better functioning. In accordance with the guidelines of the SF-36 Health Survey Manual, 9 the overall score was imputed by substituting the person specific mean scores for the completed items on that particular scale when less than 50% of the items for a particular SF-36 scale were missing. If more than half of the items for a scale were missing, that scale was considered as missing for that individual. One woman with DCIS and five with EIBC had missing scales on the SF-36. In order to compare the HRQL of women with breast cancer with the general Dutch population, SF-36 scores available from age-matched controls of the general Dutch population were used. 6 The WHO-5 contains five positively stated items. 7 Each of the five items is rated on a 6-point Likert scale from 0 (=not present) to 5 (=constantly present). The score was obtained by adding these five items. The theoretical score ranges from 0 (worst thinkable well-being) to 25 (best thinkable wellbeing), so higher scores mean better well-being. A score below 13 indicates poor well-being. 7 Missing data were handled in a similar way as for the SF-36; women had to have three or more (out of five) items completed in order to compute an overall score. One woman with DCIS and four with EIBC had missing scales on the WHO-5.
The perceived disease impact scale (PDIS) was newly developed to measure the influence of the illness on various life domains, including well-being, lifestyle, activities, relationships, work, personality, interests and trust in own body. Its 20 items were based on several sources, such as the Illness Intrusiveness scale, 10 a similar instrument to assess the impact of depression, 11 and the literature on the effects of cancer 12 and multiple sclerosis 13 on the lives of patients. The response format consisted of a 7-point Likert scale ranging from 'very negatively' (À3) to 'very positively' (+3). The following scores were derived: (1) the grand mean, averaged over all items; and following Sears and colleagues (2) the identification of any positive effect (dichotomous coding, 0 = no single positive effect versus 1 = at least one perceived benefit) and (3) the number of items with, respectively, a positive, a negative and a neutral score. 14 To assess the risk perception of recurrence and dying of breast cancer, the patient completed six questions originating from the study by Rakovitch and colleagues. 4 Three of these eight items concern the woman's estimate of her own risk of developing local recurrence, developing distance recurrence and dying of breast cancer and three items were more general items on risk perception issues. The patients were asked to answer these questions by giving an absolute percentage. The women's understanding of their diagnosis was also measured by means of two questions from the study by Rakovitch and colleagues. 4 First, the patient had to describe her disease in an open question. In addition, on an illustration depicting a normal breast, DCIS and invasive breast cancer, respectively, the patient was requested to mark the term which she felt describes her type of breast cancer best.
Statistical analysis
All data were analysed using SAS (Version 8.02, SAS Institute Inc., Cary, NC, USA). Routinely collected data from the Eindhoven Cancer Registry (ECR) on patient and tumour characteristics enabled us to compare the group of non-respondents with the group of respondents. The group of DCIS patients and the group of invasive breast cancer patients were compared by using v 2 tests for categorical variables. For continuous outcome variables, we used t-tests or Wilcoxon's signed rank test when appropriate. Fig. 1 describes the patient flow in this study. Of the 180 patients who received our questionnaire, 135 patients returned a completed questionnaire (75% response). The demographic characteristics of the overall respondents and non-respondents were not significantly different (data not shown). Mean age at the time of completing the questionnaire was 61 years for the women with DCIS (N = 33) and 59 years for the women with invasive breast cancer (N = 91). The women with DCIS did not differ from the patients with invasive breast cancer with respect to age distribution, level of education and comorbidity, but were somewhat more likely to be married (P = 0.07) ( Table 1) . Women with invasive breast cancer were more likely to have had breast-conserving therapy (P < 0.001), sentinel node biopsy (P < 0.001), radiotherapy (P < 0.001) and chemotherapy (P = 0.02) or hormonal therapy (P = 0.04).
Results
Patient and treatment characteristics
3.2.
Health-related quality of life and well-being
The mean scores on the SF-36 summary scales and domains were compared between patients with DCIS and invasive breast cancer and the available norm data of Dutch women in the same age range. No significant difference was found between women with DCIS and invasive breast cancer on the physical and the mental component scale.
Women with DCIS had a significantly better score on the subscales bodily pain (85.4 versus 75.2, P = 0.02) and general mental health (77.8 versus 70.5, P = 0.05) compared to women with invasive breast cancer. On the subscales bodily pain and the physical component scale, women with DCIS scored significantly higher than the norm data (85.4 versus 67.1, P < 0.001) and (49.6 versus 44.9, P < 0.05), respectively (Fig. 2) . Women with invasive breast cancer also had a significantly better score on the subscale bodily pain compared to the Dutch population (75.2 versus 67.1, P < 0.05) (Fig. 2) . Twenty-one percent of the women with DCIS and 35% of women with invasive breast cancer had a WHO-5 score below 13, which indicates poor well-being (P = 0.14). Mean scores of women with DCIS and invasive breast cancer were 16.3 and 14.4, respectively (P = 0.06). These scores were not different from the score in the general Dutch female population of the same age, which was 15.3. The results of both the SF-36 and the WHO-5 did not change after adjustment for differences between the two groups with respect to the type of surgery and adjuvant systemic treatment. The correlation between the WHO-5 and the physical component scale of the SF-36 was 0.58 (P < 0.001) and between the WHO-5 and the mental component scale of the SF-36 0.67 (P < 0.001). There was no association between low score on the WHO-5 (<13) and risk perception.
3.3.
Perceived disease impact scale 
Risk perception and insight into the disease
Women with DCIS and invasive breast cancer reported comparable risk perceptions concerning the risk of recurrence and dying of their disease (Table 2 ). In contrast, women with invasive breast cancer felt it more likely that the medical treatment was doing them more harm than good (P = 0.01).
When asking women to describe their disease in an open question, women with DCIS often reported the term calcifications whereas women with invasive breast cancer frequently described their disease as a (malignant) tumour. Women with DCIS were significantly more accurate in stating their diagnosis compared to women with invasive breast cancer (P = 0.02). Of the women with DCIS, 56% stated their diagnosis correctly, by marking the correct illustration, compared to only 21% of the women with invasive breast cancer. Approximately one third of the women with invasive breast cancer marked the illustration which represented DCIS (data not shown). 4.
Discussion
The results of this population-based study suggest that patients with DCIS have a similar HRQL and well-being as patients with invasive breast cancer. Also their concerns about the risk of recurrence and dying of breast cancer were generally comparable. On the physical component scale and the mental component scale, women with DCIS had similar scores compared to women with invasive breast cancer. Unexpectedly both groups experienced less bodily pain compared to the Dutch norm population. Women with DCIS also had better score on the physical component scale than the average Dutch woman with the same age. Similar findings have been reported previously and are probably due to the so-called response shift. 15 Response shift includes changes in the meaning of one's self-evaluation of HRQL resulting from changes in internal standards, values, or conceptualisation. 16 The results were not different after adjusting for type of surgical treatment and the use of adjuvant systemic therapy. Both groups reported more positive than negative effects of their disease on the different life-domains of the perceived disease impact scale. However, for patients with invasive breast cancer, the disease reportedly had more negative influences than for patients with DCIS. This seems logical because invasive breast cancer is a more serious disease than DCIS, but it is remarkable that this is not reflected in a worse HRQOL, well-being and different risk perceptions. We did not exclude women treated with mastectomy since a review comparing the impact of breast-conserving treatment and mastectomy on the HRQL found no differences between both treatments. 17 Significant differences were found on the lifedomains physical health, sex life and relationships with relatives/acquaintances. A study of Collins and colleagues in 55 cancer patients, being diagnosed within five years, also found more benefits than harm from their experiences. 12 In the psychological literature, this phenomenon is referred to as post traumatic growth or benefit finding.
14 There were no significant differences between the risk perceptions of recurrence and dying of breast cancer between the two groups. This is in accordance with the study by Rakovitch and colleagues who also found no significant difference on this item between women with invasive breast cancer and DCIS. 4 Women with DCIS made unrealistic risk estimations,
given their better prognosis compared to the women with invasive breast cancer. This high risk perception of women with DCIS may reflect the limited knowledge about the specific nature of their disease. In a population of women with no history of breast cancer, Schwartz and colleagues found that for most women DCIS is an unknown phenomenon. 18 The majority of women who are diagnosed with DCIS only know about invasive breast cancer, undergo to a great extent the same surgical treatments by oncological surgeons, which makes it understandable that they fail to have insight into the specific differences between both conditions, unless they are well-informed by health professionals. As a consequence, they also may make a wrong perception about the risk of recurrence and dying of breast cancer.
The fact that more women with DCIS than with invasive breast cancer stated their diagnosis correctly, by marking the correct illustration, is probably a chance finding, because several women commented that they did not understand the question concerning their diagnosis. This may imply that these women answered the question by guessing. This once more suggests that although women with DCIS can recall the name of the disease, they are not able to differentiate DCIS from invasive breast cancer nor do they understand its excellent prognosis. This emphasises the need of better communication by clinicians. When asking to describe their disease in an open question, a lot of women with DCIS reported the term calcifications, which does not describe the reality. Bluman and colleagues additionally demonstrated that women with DCIS had major deficiencies about knowledge of their disease, which may clarify our findings. 3 In accordance with the present study, Rakovitch and colleagues also found more women with DCIS stating their diagnosis correctly and marking the right illustration compared to women with invasive breast cancer. 4 They gave no specific reason why more women with DCIS stated their diagnosis correctly compared to women with invasive breast cancer but still reported the same risk perception as women with invasive breast cancer. More women with invasive breast cancer than with DCIS felt that medical treatment did more harm than good to them. This may be explained by the fact that more women with invasive breast cancer have undergone systemic treatment, which is known to be associated with adverse physical consequences possibly reducing the HRQL significantly. 19 The results in general are in close correspondence with the findings of the study by Rakovitch and colleagues, who conducted a similar study among Canadian patients, although at a different time point after the diagnosis. 4 Like in the present study, these investigators also failed to find significant differences between patients with DCIS and invasive breast cancer concerning risk perceptions and knowledge about the disease. Given that the women in our study were treated already two to three years ago, this finding suggests that not only the short-term but also the long-term effects of a diagnosis of DCIS on the perceived long-term HRQL are to a great extent comparable to the effects of having had invasive breast cancer. Since we did only include patients with stage I invasive breast cancer, who had not undergone axillary dissection, the whole approach, including hospitalisation and treatment, may be an important determinant of how these women experience DCIS. A potential limitation of the present study is that our DCIS sample was relatively small, despite the high response rate. This might have introduced type II errors, i.e. not finding differences which are actually present. A second limitation of the study concerns the differences between both groups with respect to the type of surgery and systemic treatment. However, adjustment for these factors in a multivariate analysis indicated that these treatment characteristics were not significant confounders.
In conclusion, the present study indicates that women with DCIS, despite their much better prognosis, failed to report a better HRQL and well-being and have similar perceptions of risk of recurrence and dying from breast cancer as women with invasive breast cancer. Concerning perceived disease impact, for the vast majority of the items no differences were found, only on some items (physical health, sex life and relationships with friends) more negative effects were reported by the invasive breast cancer patients. Surprisingly, this does not appear to affect the HRQL and well-being of these women significantly. Our findings once more seem to suggest that being diagnosed for DCIS or invasive breast cancer will not just have a negative impact on the HRQL and wellbeing. The confrontation with DCIS or invasive breast cancer rather paradoxically seems to have a generally positive impact. Both groups reported that their HRQL had improved significantly and that they had experienced many positive effects on several aspects of their life. Recent studies specifically address these issues, by focusing on concepts such as post traumatic growth and benefit finding. 20 Nevertheless, it is important that women with DCIS are informed with meticulous care about the precise nature of their disease and its very good prognosis in order to prevent unnecessary worries and distress.
